How A Biomarker Revived Synta’s Cancer Drug Elesclomol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
You may also be interested in...
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Emerging Phase III Data Validate Clinical Trial Design In Lupus
Over a span of little more than a month this summer, the face of clinical trials for lupus drugs changed considerably for the better.